Curated News
By: NewsRamp Editorial Staff
October 07, 2025
Lund University Finds Why Leukemia Evades Immune System
TLDR
- Lund University researchers discovered how leukemia cells evade immunotherapy, creating potential for new treatments that could outperform current approaches for AML patients.
- Researchers identified that leukemia cells trick the immune system, and are developing antibodies for clinical trials to address immunotherapy resistance in acute myeloid leukemia.
- This discovery could lead to more effective leukemia treatments, potentially saving lives and improving outcomes for patients with acute myeloid leukemia worldwide.
- Scientists found leukemia cells use clever deception to hide from the immune system, revealing why immunotherapy often fails against this aggressive cancer type.
Impact - Why it Matters
This discovery represents a critical advancement in cancer research that could transform treatment outcomes for leukemia patients. Acute myeloid leukemia has been particularly resistant to immunotherapy treatments that have revolutionized care for other cancers, leaving patients with limited effective options. Understanding how leukemia cells evade immune detection provides researchers with specific targets for new therapies, potentially leading to more effective treatments that could save lives and improve quality of life for those battling this aggressive disease. The development of targeted antibodies based on this research could eventually provide oncologists with new tools to combat a cancer that has proven notoriously difficult to treat successfully.
Summary
Researchers at Lund University in Sweden have made a groundbreaking discovery that explains why immunotherapy has shown limited success in treating acute myeloid leukemia (AML), a particularly aggressive form of leukemia. The study reveals that leukemia cells employ sophisticated mechanisms to evade the immune system, essentially tricking immune cells into ignoring them. This finding represents a significant breakthrough in understanding why current immunotherapies that work well for other cancers have struggled against AML, potentially opening new avenues for treatment development.
The research team has developed a specific antibody targeting this evasion mechanism and plans to advance their discovery through clinical trials toward regulatory approval. While Lund University leads this particular research, other biotechnology companies like Calidi Biotherapeutics Inc. are also exploring innovative approaches to cancer treatment, indicating broader industry interest in overcoming immunotherapy limitations. The study's findings were published through BioMedWire, a specialized communications platform focused on biotechnology and life sciences developments that provides comprehensive distribution services including wire solutions and social media outreach to reach diverse audiences across the healthcare sector.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lund University Finds Why Leukemia Evades Immune System
